external_content.pdf
There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic bur...
| Language: | English |
|---|---|
| Published: |
InTechOpen
2020
|
